Therapeutic advances in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Systemic lupus erythematosus (SLE) management involves addressing organ damage, treatment side effects, and comorbidities such as premature atherosclerosis and thrombosis.
• Current treatments for cutaneous lupus include antimalarials and thalidomide, with ongoing debate regarding optimal immunosuppression for severe cases.

Purpose of the Study:

• To review current and emerging therapeutic strategies for systemic lupus erythematosus (SLE).
• To highlight the importance of considering associated conditions and the evolving landscape of SLE treatment.

Main Methods:

• Literature review of established and novel therapeutic agents for SLE.
• Discussion of clinical experience with immunosuppressants, plasmapheresis, and bone marrow transplantation.
• Exploration of the potential of biologic therapies, including monoclonal antibodies.

Main Results:

• Established treatments like antimalarials and thalidomide are available for cutaneous lupus.
• Various immunosuppressive agents (cyclosporine, mycophenolate mofetil, dehydroepiandroepiandrosterone, intravenous immunoglobulin) are increasingly used, though plasmapheresis lacks proven benefit.
• Autologous bone marrow transplantation has been utilized in select cases.

Conclusions:

• Effective SLE management necessitates a comprehensive approach, considering organ involvement, therapy complications, and comorbidities.
• The advent of biologic therapies, particularly monoclonal antibodies, represents a significant advancement, offering potential for more targeted and effective SLE treatment.